KR102433586B1 - Food composition for relieving hangover and improving hepatic function - Google Patents
Food composition for relieving hangover and improving hepatic function Download PDFInfo
- Publication number
- KR102433586B1 KR102433586B1 KR1020200076182A KR20200076182A KR102433586B1 KR 102433586 B1 KR102433586 B1 KR 102433586B1 KR 1020200076182 A KR1020200076182 A KR 1020200076182A KR 20200076182 A KR20200076182 A KR 20200076182A KR 102433586 B1 KR102433586 B1 KR 102433586B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- calcium
- hangover
- parts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 206010019133 Hangover Diseases 0.000 title claims abstract description 46
- 230000003908 liver function Effects 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title description 11
- 229920001436 collagen Polymers 0.000 claims abstract description 68
- 102000008186 Collagen Human genes 0.000 claims abstract description 48
- 108010035532 Collagen Proteins 0.000 claims abstract description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 47
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000000284 extract Substances 0.000 claims abstract description 35
- 235000013361 beverage Nutrition 0.000 claims abstract description 33
- 241000196324 Embryophyta Species 0.000 claims abstract description 30
- 229940096421 milk thistle extract Drugs 0.000 claims abstract description 16
- 235000020727 milk thistle extract Nutrition 0.000 claims abstract description 16
- 210000004207 dermis Anatomy 0.000 claims abstract description 13
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 10
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 9
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 9
- 240000002234 Allium sativum Species 0.000 claims abstract description 4
- 235000004611 garlic Nutrition 0.000 claims abstract description 4
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 7
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 7
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 7
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 7
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 7
- 229940025878 hesperidin Drugs 0.000 claims description 7
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 7
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 7
- 229940052490 naringin Drugs 0.000 claims description 7
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 7
- 229930019673 naringin Natural products 0.000 claims description 7
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- 235000020733 paullinia cupana extract Nutrition 0.000 claims description 6
- 239000008513 turmeric extract Substances 0.000 claims description 6
- 229940052016 turmeric extract Drugs 0.000 claims description 6
- 235000020240 turmeric extract Nutrition 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229960001230 asparagine Drugs 0.000 claims description 5
- 229960004452 methionine Drugs 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 229960002898 threonine Drugs 0.000 claims 1
- 239000011575 calcium Substances 0.000 abstract description 43
- 229910052791 calcium Inorganic materials 0.000 abstract description 42
- 235000001465 calcium Nutrition 0.000 abstract description 42
- 238000002156 mixing Methods 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 174
- 235000019441 ethanol Nutrition 0.000 description 74
- 229960005069 calcium Drugs 0.000 description 41
- 230000000694 effects Effects 0.000 description 33
- 230000000052 comparative effect Effects 0.000 description 28
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000000605 extraction Methods 0.000 description 11
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 9
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 229930014626 natural product Natural products 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 241000245665 Taraxacum Species 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000035622 drinking Effects 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 7
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 5
- 241000320380 Silybum Species 0.000 description 5
- 235000010841 Silybum marianum Nutrition 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 240000003444 Paullinia cupana Species 0.000 description 4
- 235000000556 Paullinia cupana Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 244000163122 Curcuma domestica Species 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- 229960004256 calcium citrate Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 235000003373 curcuma longa Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107131 ginseng root Drugs 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 235000019997 soju Nutrition 0.000 description 2
- -1 specifically Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004267 EU approved acidity regulator Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 101000909115 Mus musculus Cytochrome P450 2E1 Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000691199 Taraxacum platycarpum Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229940087373 calcium oxide Drugs 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 229940067866 dandelion extract Drugs 0.000 description 1
- 235000020691 dandelion extract Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002214 flavonoid derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000001845 taraxacum officinale leaf extract Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 숙취 해소 및 간 기능 개선용 음료 조성물에 관한 것으로서, 진피, 갈근, 구기자 및 민들레의 식물 혼합 추출물, 밀크씨슬 추출물 및 칼슘 나노 콜라겐 펩타이드를 포함하고, 각 성분들을 특정 비율로 혼합함으로써, 숙취 해소 및 간 기능을 개선하는 것을 목적으로 한다. The present invention relates to a beverage composition for relieving a hangover and improving liver function, comprising a plant mixed extract of dermis, garlic root, goji berry and dandelion, milk thistle extract and calcium nano collagen peptide, and by mixing each component in a specific ratio, It aims to relieve hangover and improve liver function.
Description
본 발명은 숙취 해소 및 간 기능 개선용 식품 조성물에 관한 것이다. The present invention relates to a food composition for relieving hangover and improving liver function.
알코올은 적당히 섭취하면 신진대사를 촉진하고, 스트레스를 해소할 수 있는 수단이 되지만, 지나치게 과량 섭취하게 되면 갈증, 전신권태, 피로감, 기억상실, 복부팽만감, 소화불량, 구토, 설사 및 비타민 결핍 등의 숙취 현상으로 고생하게 된다.When consumed in moderation, alcohol promotes metabolism and is a means of relieving stress. However, excessive intake of alcohol can cause thirst, general malaise, fatigue, memory loss, bloating, indigestion, vomiting, diarrhea, and vitamin deficiency. suffer from hangovers.
이와 같은 숙취 현상은 간세포와 체내에 축적된 알코올 및 아세트알데하이드의 작용에 의해 발생하는 것으로 알려져 있다. 섭취된 에탄올은 소화관을 통해 흡수되어 섭취 후 20-120분 사이에 최고 혈중 농도에 도달한다. 흡수된 에탄올은 간을 비롯한 모든 장기들에서 대사되는데 일부는 호흡, 소변 또는 땀으로 배설된다. 간 내로 들어온 에탄올은 세포질 내의 알코올탈수소효소(ADH: alcohol dehydrogenase)와 알데하이드 탈수소효소(ALDH: aldehyde dehydrogenase)의 작용에 의해 아세테이트로 전환되고, 이는 순환계를 통해 간세포 밖으로 배설된다.This hangover phenomenon is known to be caused by the action of alcohol and acetaldehyde accumulated in liver cells and the body. Ingested ethanol is absorbed through the digestive tract, reaching peak blood levels between 20 and 120 minutes after ingestion. Absorbed ethanol is metabolized in all organs including the liver, some excreted through respiration, urine or sweat. Ethanol entering the liver is converted into acetate by the action of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cytoplasm, which is excreted out of the liver cells through the circulation.
에탄올의 최초 대사산물인 아세트알데하이드는 에탄올에 비해 반응성이 매우 높고 독성이 강하여 알코올성 간 장애의 주원인 물질로 밝혀진 바 있다. 아세트알데하이드는 세포 내 에너지 생성기관인 미토콘드리아의 호흡을 방해하고 산화적 인산화 반응을 억제하며, 면역학적으로 세포독성을 나타내어 간세포 분비 단백질의 방출기구를 저해하는 것으로 밝혀진 바 있다. 또한 아세트알데하이드는 근섬유모세포(myofibroblast)의 콜라겐 합성을 촉진하여 간 섬유화와 간세포의 변성 종대를 일으키며, 생체 내 거대분자와 반응하여 부가물(adduct)을 형성하기도 한다. 특히, 알데하이드 탈수소효소 중 미토콘드리아에 존재하는 타입 II가 아세트알데하이드의 제거에 중요한데, 동양인은 일반적으로 II형 효소가 결핍 또는 부족하기 때문에 아세트알데하이드 산화가 느리고 따라서 산화되지 않은 아세트알데하이드 및 에탄올의 유독 작용에 의하여 정상적인 신진대사가 방해받아 여러 숙취 현상을 느끼게 되는 것이다.Acetaldehyde, the first metabolite of ethanol, has been found to be the main cause of alcoholic liver disorders because it is highly reactive and more toxic than ethanol. It has been found that acetaldehyde interferes with the respiration of mitochondria, an energy-generating organ within cells, inhibits oxidative phosphorylation, and exhibits immunological cytotoxicity to inhibit the release mechanism of hepatocyte-secreted proteins. In addition, acetaldehyde promotes collagen synthesis in myofibroblasts, causing liver fibrosis and degenerative enlargement of hepatocytes, and also forms adducts by reacting with macromolecules in vivo. In particular, among aldehyde dehydrogenases, type II present in mitochondria is important for the removal of acetaldehyde. Asians generally lack or lack the type II enzyme, so acetaldehyde oxidation is slow, and thus, the toxic action of unoxidized acetaldehyde and ethanol is critical. This disrupts the normal metabolism and causes various hangover phenomena.
간은 당질, 단백질, 지방을 대사하는 중심기관이며, 체내에 들어온 물질을 산환, 환원, 가수분해 및 포합반응을 통해 체내로 배설하는 기능을 담당하는 중요한 기관이다. 그러나 간질환이 초기단계에서 통증이나 자각증상이 잘 나타나지 않고 상당히 악화되어서야 발견되어 간은 '침묵의 장기'로도 알려져 있다.The liver is a central organ that metabolizes carbohydrates, proteins, and fats, and is an important organ responsible for excreting substances into the body through oxidation, reduction, hydrolysis and conjugation reactions. However, the liver is also known as the 'silent organ', as liver disease is discovered only after a significant deterioration in pain or subjective symptoms in the early stages.
간 손상의 원인에는 간염바이러스(A, B, C 등), 알코올(음주), 그리고 비알코올성 지방간, 약물 또는 독성 간염 등이 대부분이고, 그 외에 드문 원인들이 있다. 건강보험심사평가원 통계에 따르면 최근 국내 알코올성 간질환으로 발생되는 치료비용은 매년 급증하는 추세다. 또한 국내 한 생명보험사의 통계를 분석해 봐도 사망 원인 중 알코올성 간질환 사망자가 10년 전과 비교해 7배로 급증했다. 지속적인 알코올 섭취로 인해 유발되는 알코올성 간질환은 국내를 비롯한 전 세계적인 사회적인 문제로 대두되고 있는데, 특히 알코올성 지방간 및 간염이 지속되면 간 섬유화 및 간 경변으로 더 이상 회복을 기대할 수 없는 단계에 이르게 되어 간 이식만이 유일한 치료방법으로 남게 된다.Most of the causes of liver damage are hepatitis virus (A, B, C, etc.), alcohol (drinking), and non-alcoholic fatty liver, drugs or toxic hepatitis, and there are other rare causes. According to statistics from the Health Insurance Review and Assessment Service, the cost of treatment for alcoholic liver disease in Korea is increasing every year. Also, analyzing the statistics of a domestic life insurance company, the number of deaths from alcoholic liver disease among the causes of death increased seven times compared to 10 years ago. Alcoholic liver disease caused by continuous alcohol intake is emerging as a social problem worldwide, including in Korea. In particular, if alcoholic fatty liver and hepatitis continue, liver fibrosis and cirrhosis of the liver reach a stage where recovery is no longer expected. It remains the only treatment option.
간 질환 중에서 만성적인 음주에 의해 발생하는 질환은 알코올성 지방간, 알코올성 간염, 알코올성 간경변으로 크게 나누어지지만 한 사람에게서 순수한 한 가지 병만 나타나는 경우는 드물고, 각 병이 개인마다 다양한 정도로 나타나게 된다. 미국에서는 가장 흔한 간 경변의 원인이며 우리나라에서는 바이러스성 간염 다음으로 흔한 간경변의 원인이기도 하다.Among liver diseases, diseases caused by chronic drinking are largely divided into alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis, but it is rare that only one pure disease appears in one person, and each disease appears to varying degrees for each individual. It is the most common cause of cirrhosis in the United States and the second most common cause of cirrhosis in Korea after viral hepatitis.
한편, 천연물로부터 인간의 질병을 예방, 치료하거나 각종 기능을 개선할 수 있는 건강기능식품 등으로 이용할 수 있는 신물질을 탐색하는 것은 과거부터 많은 과학자들의 연구대상이 되어왔다. 이와 같은 천연자원의 개발을 통해, 현재 사용되고 있는 의약품의 50% 이상이 천연물로부터 유래되었으며 미국 FDA로부터 승인된 천연물 의약 품도 120종 가량으로 이들의 시장규모는 약 10조 달러에 이르고 있다.On the other hand, searching for new substances that can be used as health functional foods that can prevent or treat human diseases or improve various functions from natural products has been the subject of research by many scientists from the past. Through the development of such natural resources, more than 50% of currently used medicines are derived from natural products, and there are about 120 types of natural medicines approved by the US FDA, and their market size is about 10 trillion dollars.
숙취 해소에 대해서는 대한민국 공개특허 제2002-0081995호(배합식품에 의한 숙취 해소 및 간 기능 개선제와 그 제조방법), 대한민국 공개특허 제2002-0064151호(헛개나무로부터 분리된 간독성 및 숙취해소 활성을 갖는 저급 알코올 불용성 추출 분획 및 다당체 물질 및 이를 함유하는 조성물) 등의 특허에 쌀눈엑스(구루메), 오리나무, 참나무 목초액, 갈화, 밀크씨슬 추출물 등의 여러 가지 식물에서 기원한 제제들이 숙취에 효능이 있다고 보고되어 있긴 하지만, 이들은 음주에 의해 유발되는 다양한 변화들 중에서 일부 항목에만 효과가 있거나 미미한 것으로 나타나고 있는 것으로 알려져 있다.For hangover relief, Korean Patent Laid-Open No. 2002-0081995 (Hangover Relief and Liver Function Improvement Agent and Method for Manufacturing the Same by Formulated Food), Republic of Korea Patent Publication No. 2002-0064151 (with hepatotoxicity and hangover relieving activity isolated from H. In patents such as lower alcohol insoluble extract fractions and polysaccharide substances and compositions containing them), various plant-derived preparations such as rice nun extract (gurume), alder, oak wood vinegar, brown flower, and milk thistle extract are effective for hangovers. Although it is reported that there is, it is known that these are effective or insignificant in only some of the various changes induced by drinking.
따라서, 간 건강에 관련된 기능식품 개발 방향은 간 건강 유지에 도움을 주는 단일 천연물을 원료로 하는 식품보다는 간 질환을 유발하는 각각의 요인에 대한 효능을 가지고 있는 천연물을 복합한 제제개발이 유리하며, 이를 위해서는 많은 천연물을 대상으로 하여 간 질환 요인 별 활성 평가가 필요한 실정이라고 할 수 있다.Therefore, in the direction of the development of functional food related to liver health, it is advantageous to develop a complex formulation of natural products that have effects on each factor that causes liver disease, rather than foods made from a single natural product that helps maintain liver health. To this end, it can be said that it is necessary to evaluate the activity of each liver disease factor by targeting many natural products.
본 발명의 발명자들은 식물이 갖는 다양한 생리활성을 연구하던 중, 특정 식물 혼합 추출물, 밀크씨슬 추출물 및 칼슘 나노 콜라겐 펩타이드를 포함하는 조성물이 숙취 해소 및 간 기능 개선에 효능이 뛰어남을 확인하여 본 발명을 완성하게 되었다. The inventors of the present invention, while studying various physiological activities of plants, confirmed that a composition containing a specific plant mixed extract, milk thistle extract and calcium nano-collagen peptide is effective in relieving hangover and improving liver function. was completed.
본 발명은 진피, 갈근, 구기자 및 민들레의 식물 혼합 추출물, 밀크씨슬 추출물 및 칼슘 나노 콜라겐 펩타이드를 포함하고, 각 성분들을 특정 비율로 혼합함으로써, 숙취 해소 및 간 기능을 개선하는 것을 목적으로 한다. The present invention includes a plant mixed extract of dermis, ginseng root, goji berry and dandelion, milk thistle extract and calcium nano collagen peptide, and by mixing each component in a specific ratio, it aims to relieve hangover and improve liver function.
또한, 천연물을 유효성분으로 사용함으로써 인체에 안전하게 숙취 해소 및 간 기능을 개선시키는 것을 목적으로 한다. In addition, it aims to relieve a hangover and improve liver function safely in the human body by using a natural product as an active ingredient.
진피, 갈근, 구기자 및 민들레의 식물 혼합 추출물, 밀크씨슬 추출물 및 칼슘 나노 콜라겐 펩타이드를 포함하되, 조성물 총 중량 대비Including plant mixed extracts of dermis, ginseng root, goji berry and dandelion, milk thistle extract and calcium nano collagen peptide, compared to the total weight of the composition
상기 식물 혼합 추출물은 70 내지 90 중량부이고, The plant mixed extract is 70 to 90 parts by weight,
상기 밀크씨슬 추출물은 1 내지 10 중량부이며, The milk thistle extract is 1 to 10 parts by weight,
상기 칼슘 나노 콜라겐 펩타이드는 조성물 0.3 내지 5 중량부인 것을 특징으로 하는 숙취 해소 및 간 기능 개선용 식품 조성물, 보다 구체적으로는 음료 조성물을 제공한다. The calcium nano-collagen peptide provides a food composition for relieving a hangover and improving liver function, characterized in that 0.3 to 5 parts by weight of the composition, more specifically, a beverage composition.
본 발명은 진피, 갈근, 구기자 및 민들레의 식물 혼합 추출물, 밀크씨슬 추출물 및 칼슘 나노 콜라겐 펩타이드를 특정 비율로 혼합함으로써, 숙취를 빠르게 해소시키고, 간 기능을 개선할 수 있는 효과를 제공한다. The present invention provides the effect of quickly relieving a hangover and improving liver function by mixing the plant extract, milk thistle extract, and calcium nano collagen peptide of dermis, garlic root, goji berry and dandelion in a specific ratio.
또한, 본 발명은 천연물을 유효성분으로 사용함으로써 인체에 안전한 효과가 있다. In addition, the present invention has a safe effect on the human body by using a natural product as an active ingredient.
이하, 본 발명에 대한 이해를 돕기 위해 본 발명을 더욱 상세하게 설명한다. 이때, 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Hereinafter, the present invention will be described in more detail to help the understanding of the present invention. At this time, the terms or words used in the present specification and claims are not to be construed as being limited to conventional or dictionary meanings, and the inventor appropriately defines the concept of the term in order to explain his invention in the best way. It should be interpreted as meaning and concept consistent with the technical idea of the present invention based on the principle that it can be done.
본 발명은 숙취 해소 및 간 기능 개선용 식품 조성물에 관한 것으로서, 숙취에 따른 여러 증상을 예방 및 개선하고, 간 기능을 개선하는 것을 목적으로 한다.The present invention relates to a food composition for relieving a hangover and improving liver function, and an object of the present invention is to prevent and improve various symptoms caused by a hangover, and to improve liver function.
구체적으로, 본 발명의 숙취 해소 및 간 기능 개선용 식품 조성물은 진피, 갈근, 구기자 및 민들레의 식물 혼합 추출물, 밀크씨슬 추출물 및 칼슘 나노 콜라겐 펩타이드를 포함할 수 있다. Specifically, the food composition for relieving hangover and improving liver function of the present invention may include a plant mixed extract of dermis, ginseng root, goji berry and dandelion, milk thistle extract and calcium nano collagen peptide.
본 발명의 식물 혼합 추출물은 혈액 순환 촉진, 수분 대사 촉진, 알코올 분해, 해독, 두통 예방, 이뇨 작용, 심신 안정 및 스트레스 완화 작용을 통해 숙취를 해소하고, 지방간을 예방하고, 간 기능을 개선시키는 효과가 있다. The plant mixed extract of the present invention has the effect of relieving a hangover, preventing fatty liver, and improving liver function by promoting blood circulation, water metabolism, alcohol decomposition, detoxification, headache prevention, diuretic action, mental and physical stability, and stress relieving action. there is
구체적으로 진피는, 운향과의 귤(Citrus unshiu Markovich) 또는 동속 근연식물의 성숙한 과피를 말한다. 진피는 기가 뭉친 것을 풀어주고 비장의 기능을 강화해주고, 이뇨 작용을 한다. 또한, 비타민 C가 풍부하여 신진대사 촉진, 혈액순환 촉진, 피로회복 등에 도움을 주며, 감귤류 과일에 많이 존재하는 헤스페리딘(Hesperidin)에 의해 지질과산화물 형성을 억제하며, 노화 지연 등의 항산화 효과, 항염증 효과, 모세혈관 보호 및 항암 작용, 콜레스테롤을 낮추는 효과가 있다. 또한 진피 추출물은 알코올에 의한 간세포 보호 효과 및 알코올 분해에 효과가 있다.Specifically, the dermis refers to the mature pericarp of Citrus unshiu Markovich or a related plant of the rutaceae family. The dermis releases qi clumping, strengthens the function of the spleen, and acts as a diuretic. In addition, it is rich in vitamin C, which promotes metabolism, promotes blood circulation, and helps to recover from fatigue. Effect, capillary protection and anticancer action, cholesterol lowering effect. In addition, the dermis extract has an effect on hepatocellular protection and alcohol breakdown by alcohol.
또한, 갈근 또는 칡(Pueraria lobata Ohwi)은, 여러해살이식물로서 겨울에도 얼어 죽지 않고 대부분의 줄기가 살아남는다. 줄기는 매년 굵어져서 굵은 줄기를 이루기 때문에 나무로 분류된다. 한방에서는 뿌리를 갈근(葛根)이라는 약재로 쓰는데, 발한·해열, 숙취 해소 등에 효과가 있다. 갈근(칡뿌리)은 daidzin과 puerarin 및 카테킨 성분이 풍부하게 함유되어 있어 간 기능 향상, 간 기능 회복, 숙취해소 및 해독작용 등의 효능을 가지고 있다.Also, Pueraria lobata Ohwi, a perennial plant, does not freeze to death even in winter, and most of its stems survive. It is classified as a tree because its trunk grows thicker every year to form a thick trunk. In oriental medicine, the root is used as a medicinal herb called galgeun (葛根), which is effective in relieving sweating, fever, and hangover. As it contains abundant daidzin, puerarin, and catechin components, it has the effects of improving liver function, restoring liver function, relieving hangover, and detoxifying.
또한, 구기자(Lycium dhinense Mill)는, 콜린대사물질의 하나인 베타인이 풍부해서 간에 지방이 축적되는 것을 억제하는데 도움을 주어 지방간을 예방하는 효과가 있으며, 비타민C, 루틴 등이 있어 혈관을 튼튼하게 하고, 피로회복 에 도움이 된다. 또한 알코올 분해효소인 Alcohol dehydrogenase(ADH)와 아세트알데하이드 분해효소인 aldehyde dehydrogenase(ALDH)의 활성을 증가시켜 알코올 분해대사를 촉진한다.In addition, goji (Lycium dhinense Mill) is rich in betaine, one of the choline metabolites, which helps to inhibit the accumulation of fat in the liver, thereby preventing fatty liver. and helps in relieving fatigue. In addition, it increases the activity of alcohol dehydrogenase (ADH), an enzyme that decomposes alcohol, and aldehyde dehydrogenase (ALDH), an enzyme that decomposes acetaldehyde, thereby promoting alcohol decomposition.
또한, 민들레(Taraxacum platycarpum)에 풍부하게 함유된 루테오린이라는 성분은 항염증 작용을 하여 염증을 다스리는데 효과가 있으며, 민들레 속의 풍부한 폴리페놀은 체내 활성 산소 억제에 효과가 있고, 비타민 A 및 비타민 C가 풍부하여 피로회복 및 항산화 작용, 숙취 및 간 기능 부전에 의한 혈액 내 염증을 완화시키는데 효과가 있다. 또한 민들레 추출물을 섭취하면 음주로 인한 지방간이 완화되고, 간 기능이 개선되며, 아세트알데하이드 분해효소인 aldehyde dehydrogenase(ALDH)의 활성을 증가시켜 혈중 아세트알데하이드의 농도를 감소시킨다.In addition, a component called luteolin, which is abundantly contained in dandelion (Taraxacum platycarpum), has anti-inflammatory action and is effective in controlling inflammation. Rich in C, it is effective in relieving fatigue, antioxidant action, and alleviating inflammation in the blood caused by hangover and liver failure. In addition, consumption of dandelion extract relieves fatty liver caused by drinking, improves liver function, and increases the activity of aldehyde dehydrogenase (ALDH), an acetaldehyde decomposing enzyme, to decrease the concentration of acetaldehyde in the blood.
한편, 본 발명의 식물 혼합 추출물은 각 성분의 효능을 고려하여 적절한 비율로 식물을 혼합시켜 추출함으로써, 최적의 숙취 해소 및 간 기능 개선 효과를 나타내는 것을 특징으로 한다. On the other hand, the plant mixed extract of the present invention is characterized in that it exhibits an optimal effect of relieving hangover and improving liver function by mixing and extracting plants in an appropriate ratio in consideration of the efficacy of each component.
구체적으로, 본 발명의 진피, 갈근, 구기자 및 민들레가 5:5:4:4의 중량비로 혼합된 것일 수 있다. Specifically, the dermis of the present invention, galgeun, goji berry and dandelion may be mixed in a weight ratio of 5:5:4:4.
한편, 상기 식물 혼합 추출물은 감압고온추출, 열탕추출, 환류추출, 열수추출, 냉침 추출, 상온추출, 초음파추출 또는 증기추출 방법으로 추출할 수 있으나, 이에 제한되는 것은 아니다. On the other hand, the plant mixed extract may be extracted by vacuum high temperature extraction, hot water extraction, reflux extraction, hot water extraction, cold extraction, room temperature extraction, ultrasonic extraction or steam extraction method, but is not limited thereto.
구체적으로 본 발명의 식물 혼합 추출물은 혼합된 식물을 물 및 C1 내지 C4의 직쇄 또는 분지쇄형 알코올로 이루어진 군으로부터 선택되는 1종 이상의 용매로 1회 또는 수 회 이상 반복 추출하여 얻을 수 있으며, 보다 구체적으로 상기 천연물 혼합 추출물은 천연물 혼합 원료의 약 5 내지 10배의 물 및/또는 50% 에탄올로 약 100 ℃에서 약 10 시간 이상 동안 수 회 반복 추출된 것이 바람직하다. Specifically, the plant mixed extract of the present invention can be obtained by repeatedly extracting the mixed plant once or several times or more with one or more solvents selected from the group consisting of water and C1 to C4 linear or branched alcohols, more specifically As such, it is preferable that the natural product mixture extract is repeatedly extracted several times for about 10 hours or more at about 100° C. with about 5 to 10 times the amount of water and/or 50% ethanol of the natural product mixture raw material.
상기 추출물은 통상의 방법에 따라, 유기용매(알코올, 에테르 아세톤 등)에 의한 추출, 헥산과 물의 분배, 칼럼크로마토그래피에 의한 방법 등, 식물체 성분의 분리 추출에 이용되는 공지의 방법을 단독 또는 적합하게 조합한 방법을 이용하여 분획 또는 정제하여 사용할 수 있다.The extract is a known method used for separation and extraction of plant components, such as extraction with an organic solvent (alcohol, ether acetone, etc.), distribution of hexane and water, and a method by column chromatography according to a conventional method alone or suitable It can be used after fractionation or purification using a combination method.
또한, 본 발명의 음료 조성물은 밀크씨슬 추출물을 포함하는 것을 특징으로 한다. In addition, the beverage composition of the present invention is characterized in that it comprises a milk thistle extract.
밀크씨슬(Milk Thistle)은 엉겅퀴 식물의 일종으로 보라색 꽃을 피우는 국화과의 약용식물로서, 열매와 씨에는 플라보노리그난이 함유되어 있으며 주요 구성 성분은 총칭하여 실리마린(Silymarin)이라고 한다. 실리마린은 매우 강력한 항독성 물질로 간에서 독성 물질을 제거하여 간을 보호하고, 간 기능을 개선한다. 밀크씨슬은 또한 알코올의 중화와 해독, 간 질환 완화, 활성 산소로부터 간 세포 보호, 면역 기능 강화에 효능이 있을 뿐만 아니라, 글루타치온의 농도를 증가시키고 그 결핍을 예방함으로써 알코올로 인해 손상된 간 세포를 복구하고 간 조직을 재생하여 간을 건강히 유지하는데 도움을 준다. Milk Thistle is a kind of milk thistle, a medicinal plant of the Asteraceae family that blooms purple flowers. The fruit and seeds contain flavonolignans, and the main constituents are collectively called Silymarin. Silymarin is a very strong anti-toxic substance that protects the liver by removing toxic substances from the liver and improves liver function. Milk thistle is also effective in neutralizing and detoxifying alcohol, relieving liver disease, protecting liver cells from free radicals, and enhancing immune function. Helps to keep the liver healthy by repairing and regenerating liver tissue.
글루타치온은 글라이신, 글루타메이트, 시스테인 세 가지 아미노산이 결합되어 이루어진 단백질(트리펩타이드)이며, 간에서 생산되는 수용성의 가장 강력한 항산화제로서 암 억제 및 항노화 영양소를 가진 주재료이다. 일반적으로 유독 물질, 알코올 등의 대사가 이루어지는 간에 글루타치온의 농도가 가장 많으며, 독성물질을 대사하여 담즙으로 배설시킨다. 글루타치온은 간과 세포에서 프리라디컬을 제거하여 세포손상을 방지하여 과음으로부터 간을 보호할 수 있다.Glutathione is a protein (tripeptide) composed of three amino acids combined with glycine, glutamate, and cysteine. As the most water-soluble and powerful antioxidant produced by the liver, it is the main ingredient with anti-cancer and anti-aging nutrients. In general, the concentration of glutathione is the highest in the liver where toxic substances and alcohol are metabolized, and toxic substances are metabolized and excreted in bile. Glutathione can protect the liver from excessive drinking by removing free radicals from the liver and cells to prevent cell damage.
따라서, 밀크씨슬은 모든 유형의 만성 간 질환, 특히 알코올성 음료의 규칙적인 음주로 인한 지방간을 치료하기 위해 널리 사용될 수 있다.Therefore, milk thistle can be widely used to treat all types of chronic liver disease, especially fatty liver caused by regular drinking of alcoholic beverages.
또한, 본 발명의 음료 조성물은 칼슘 나노 콜라겐 펩타이드를 포함하는 것을 특징으로 한다. In addition, the beverage composition of the present invention is characterized in that it contains calcium nano-collagen peptide.
상기 칼슘 나노 콜라겐 펩타이드는 하기 화학식 1로 표시되는 나노 콜라겐 펩타이드일 수 있다. The calcium nano-collagen peptide may be a nano-collagen peptide represented by the following Chemical Formula 1.
[화학식 1][Formula 1]
(R은 아미노산의 종류를 결정짓는 곁사슬을 나타내고, M은 Ca 이다.) (R represents the side chain that determines the type of amino acid, and M is Ca.)
본 발명의 칼슘 나노 콜라겐 펩타이드는 나노 단위의 콜라겐 펩타이드와 미네랄인 칼슘이 킬레이트화된 복합체로서, 식품, 의약품, 의약외품, 화장품 또는 사료 등에 사용될 수 있고, 이 경우 제품의 보존성 및 안정성을 개선시키며, 피부 또는 체내에 펩타이드뿐 아니라 콜라겐 펩타이드에 킬레이트화된 칼슘의 흡수율을 개선시키는 효과가 있다. The calcium nano-collagen peptide of the present invention is a complex in which nano-unit collagen peptides and calcium, which is a mineral, are chelated, and can be used in food, medicine, quasi-drugs, cosmetics or feed, etc. In this case, it improves the preservation and stability of the product, and improves skin Alternatively, there is an effect of improving the absorption rate of calcium chelated to collagen peptides as well as peptides in the body.
상기 칼슘 나노 콜라겐 펩타이드는 1) 콜라겐에 효소를 첨가하여 가수분해 반응시켜 나노 단위의 사이즈를 갖는 콜라겐 펩타이드를 형성하는 단계; 및 2) 상기 콜라겐 펩타이드에 칼슘을 첨가하여 칼슘 나노 콜라겐 펩타이드 킬레이트를 형성하는 단계를 통해 제조될 수 있다. The calcium nano-collagen peptide is prepared by: 1) adding an enzyme to collagen to hydrolyze it to form a collagen peptide having a nano-unit size; and 2) adding calcium to the collagen peptide to form a calcium nano-collagen peptide chelate.
콜라겐은 경단백질 또는 교원질(膠原質)이라고도 하고, 무척추동물이나 척추동물 등의 다세포동물에 널리 분포하며 양적으로도 가장 많이 발견되는 경단백질로서 사람의 몸에서 장기를 감싸는 막, 관절 연골, 눈의 각막, 뼈와 피부 등에 주로 존재하고, 특히 피부 속 진피층의 구성 성분으로 매우 중요한 역할을 하고 있다. 콜라겐의 주된 기능은 피부의 견고성, 조직의 저항력과 결합력, 세포접착의 지탱 등이 알려져 있다.Collagen, also called hard protein or collagen, is widely distributed in multicellular animals such as invertebrates and vertebrates and is the most quantitatively found hard protein in the human body. It is mainly present in the cornea, bones and skin, and plays a very important role as a component of the dermis layer in the skin. It is known that the main function of collagen is the firmness of the skin, the resistance and bonding of tissues, and the support of cell adhesion.
콜라겐은 크게 우피, 돈피 등의 동물성 콜라겐, 과실류, 채소류, 종자류, 견과류, 버섯류 등의 식물성 콜라겐, 해조류, 어류, 어류비늘, 어피 등의 해양성 콜라겐으로 나눌 수 있으며, 본 발명의 칼슘 나노 콜라겐 펩타이드 제조에 사용되는 콜라겐은 동물성 콜라겐, 식물성 콜라겐 및 해양성 콜라겐으로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 한다.Collagen can be largely divided into animal collagen such as cow skin and pig skin, vegetable collagen such as fruits, vegetables, seeds, nuts and mushrooms, and marine collagen such as seaweed, fish, fish scales, and fish skin, and production of calcium nano collagen peptide of the present invention Collagen used for this is characterized in that at least one selected from the group consisting of animal collagen, vegetable collagen, and marine collagen.
콜라겐은 세 개의 폴리펩티드 사슬이 꼬여 있는 삼중나선형 구조를 가지고 있으며, 콜라겐의 평균 분자량은 30만 Da(Dalton, 달톤)으로 분자량이 큰 편이다. 이와 같이 분자량이 큰 콜라겐의 체내 흡수율을 증가시키기 위해서 본 발명의 칼슘 나노 콜라겐 펩타이드는 효소를 첨가하여 상기 콜라겐을 가수분해 반응시켜 나노 단위의 콜라겐 펩타이드로 분해하는 단계를 통해 제조된다. Collagen has a triple helix structure in which three polypeptide chains are twisted, and the average molecular weight of collagen is 300,000 Da (Dalton, Dalton), which is high. In order to increase the absorption rate of collagen having a large molecular weight in the body, the calcium nano-collagen peptide of the present invention is prepared through a step of decomposing the collagen into nano-unit collagen peptides by adding an enzyme to hydrolyze the collagen.
본 발명의 콜라겐 펩타이드의 평균 분자량은 200 Da 내지 600 Da, 보다 구체적으로는 300 Da 내지 400 Da 이고, 그 사이즈는 0.1 nm 내지 10 nm, 보다 구체적으로는 1 nm 내지 5 nm 로 나노화되어 있는 바, 그 작은 분자량과 작은 크기로 인해 체내 또는 피부에 빠르게 흡수되는 효과를 나타낸다.The collagen peptide of the present invention has an average molecular weight of 200 Da to 600 Da, more specifically 300 Da to 400 Da, and a size of 0.1 nm to 10 nm, more specifically 1 nm to 5 nm. Due to its small molecular weight and small size, it has the effect of being rapidly absorbed into the body or skin.
여기서, 상기 콜라겐 나노화 단계에 사용되는 효소는 단백질 분해효소로서, 콜라게나아제, 트립신, 파파인, 펩신 및 알칼라제로 이루어진 군에서 선택되는 1종 이상을 포함하는 것을 특징으로 하며, 콜라겐을 콜라겐 펩타이드로 분해하는 가수분해 반응은 50 ℃ 내지 70 ℃, 보다 구체적으로는 50 ℃ 내지 60 ℃ 에서 2 시간 내지 24 시간 동안 수행되는 것을 특징으로 한다.Here, the enzyme used in the collagen nano-forming step is a proteolytic enzyme, characterized in that it comprises at least one selected from the group consisting of collagenase, trypsin, papain, pepsin, and alcalase, and converting collagen into collagen peptides. The decomposing hydrolysis reaction is characterized in that it is carried out at 50 °C to 70 °C, more specifically, at 50 °C to 60 °C for 2 hours to 24 hours.
상기 범위의 온도 및 시간의 조건 하에 가수분해 반응이 일어나는 경우 체내 흡수율이 높은 적절한 분자량 및 크기의 콜라겐 펩타이드를 얻을 수 있다.When the hydrolysis reaction occurs under the conditions of temperature and time within the above range, it is possible to obtain a collagen peptide having an appropriate molecular weight and size having a high absorption rate in the body.
콜라겐 나노화 단계 이후, 2) 1)단계를 통해 얻은 상기 콜라겐 펩타이드에 칼슘을 첨가하여 칼슘 나노 콜라겐 펩타이드 킬레이트를 제조할 수 있다. After the collagen nano-ing step, 2) calcium nano-collagen peptide chelate can be prepared by adding calcium to the collagen peptide obtained through 1) step.
킬레이트란, 금속이온과 배위결합을 하는 배위기를 1분자 내에 복수로 갖는 배위자가 금속과 배위결합 했을 때의 결합, 또는 그 결합에 의하여 생성된 복합체를 의미한다. 본 발명에서는, 아미노산의 알파탄소에 결합된 아미노기의 공유결합에 참여하지 못한 비공유 전자쌍이 미네랄과 완전한 배위결합을 이루어 칼슘 나노 콜라겐 펩타이드 킬레이트를 형성하게 된다.The chelate refers to a bond when a ligand having a plurality of coordination groups for coordinating a metal ion in one molecule is coordinated with a metal, or a complex formed by the bonding. In the present invention, the lone pair of electrons that do not participate in the covalent bond of the amino group bonded to the alpha carbon of the amino acid forms a complete coordination bond with the mineral to form a calcium nano-collagen peptide chelate.
본 발명에서 사용되는 칼슘은 탄산칼슘, 염화칼슘, 젖산칼슘, 구연산칼슘, 글루콘산칼슘, 글리세로인산칼슘, 산화칼슘, 수산화칼슘, 제삼인산칼슘, 제이인산칼슘, 황산칼슘, 기타 식품원료를 사용하여 칼슘을 보충할 수 있도록 제조 가공한 것일 수 있다. Calcium used in the present invention is calcium carbonate, calcium chloride, calcium lactate, calcium citrate, calcium gluconate, calcium glycerophosphate, calcium oxide, calcium hydroxide, tricalcium phosphate, dibasic calcium phosphate, calcium sulfate, and other food ingredients. It may be manufactured and processed to supplement the.
사용되는 칼슘은 콜라겐 펩타이드 100 중량 대비 1 내지 20 중량부인 것을 특징으로 하며, 상기 범위 내에서 미반응의 칼슘 없이 칼슘 나노 콜라겐 펩타이드를 고순도로 얻을 수 있다.Calcium used is characterized in that 1 to 20 parts by weight based on 100 parts by weight of the collagen peptide, and within the above range, calcium nano-collagen peptides can be obtained with high purity without unreacted calcium.
칼슘 나노 콜라겐 펩타이드는 콜라겐이 나노 크기의 펩타이드로 가수분해되어 있는 바, 종래의 콜라겐 대비 생체 흡수율 및 이용률이 극대화될 수 있다.In the calcium nano-collagen peptide, collagen is hydrolyzed into nano-sized peptides, so the bioabsorption rate and utilization rate can be maximized compared to conventional collagen.
또한, 체내의 칼슘 흡수율을 증가시키고, 생체 이용률을 극대화시키는데 도움을 준다. 칼슘은 식품에 사용할 경우, 체내 칼슘을 보급하여 뼈와 치아 형성에 도움을 주고, 치조골을 강화시켜 주어 잇몸을 건강하게 하며, 신경과 근육 기능 유지, 골다공증 발생 위험 감소효과가 있으며, 세포막의 전위차 평형을 맞춰주어 혈관 질환과 심장 질환에 도움을 줄 수 있다. In addition, it increases the absorption rate of calcium in the body and helps to maximize the bioavailability. When used in food, calcium helps the formation of bones and teeth by supplying calcium in the body, strengthens alveolar bone to keep gums healthy, maintains nerve and muscle functions, reduces the risk of osteoporosis, and balances the potential difference of cell membranes It can help with vascular disease and heart disease.
또한, 본 발명의 칼슘 나노 콜라겐 펩타이드는 배위공유결합을 통해 콜라겐 펩타이드와 칼슘을 단단히 결합시킴으로써 음이온 결합 및 경쟁 흡수를 예방하여 소장까지 도달하는 칼슘의 양을 극대화할 수 있다. 나아가, 효소에 의해 이온화되지 않아도 흡수가 가능하므로 소장 상단부뿐만 아니라 소장 전체에서 흡수될 수 있다. 또한, 콜라겐 펩타이드와의 결합을 통해 지용성을 확보할 수 있고 이로써 세포막 전체에서 흡수될 수 있으며 이에 따라 소장에서 세포로 흡수되는 칼슘의 양을 극대화할 수 있다. 나아가, 비타민 D의 영향을 최소화함으로써 칼슘 흡수가 안정적으로 이루어지도록 할 수 있다.In addition, the calcium nano-collagen peptide of the present invention can maximize the amount of calcium reaching the small intestine by tightly binding the collagen peptide and calcium through coordination covalent bonding, thereby preventing anion binding and competitive absorption. Furthermore, since absorption is possible without being ionized by enzymes, it can be absorbed not only in the upper part of the small intestine but also in the entire small intestine. In addition, fat solubility can be secured through binding with collagen peptide, and thus can be absorbed from the entire cell membrane, thereby maximizing the amount of calcium absorbed into cells from the small intestine. Furthermore, by minimizing the effect of vitamin D, calcium absorption can be made stably.
본 발명에서 상기 칼슘 나노 콜라겐 펩타이드는 미네랄 공급, 체내 이온 균형 및 양질의 단백질 공급원으로서의 역할을 수행하여 신경 안정, 위 점막 보호, 숙취 해소 및 간 기능을 개선하는 역할을 한다. In the present invention, the calcium nano-collagen peptide serves as a mineral supply, ion balance in the body, and serves as a high-quality protein source to stabilize nerves, protect gastric mucosa, relieve hangover, and improve liver function.
여기서 본 발명의 음료 조성물은, 상기 진피, 갈근, 구기자 및 민들레의 식물 혼합 추출물, 밀크씨슬 추출물 및 칼슘 나노 콜라겐 펩타이드를 특정 중량비로 혼합된 것을 특징으로 하며, 구체적으로, 본 발명의 조성물은 숙취 증상의 정도, 증상의 진행 정도, 간 건강 상태에 따라서 적절히 조절 가능하나, 조성물 총 중량 대비 상기 식물 혼합 추출물은 70 내지 90 중량부, 구체적으로는 70 내지 80 중량부이고, 상기 밀크씨슬 추출물은 1 내지 10 중량부, 구체적으로는 1 내지 5 중량부이며, 상기 칼슘 나노 콜라겐 펩타이드는 0.3 내지 10 중량부, 구체적으로는 0.3 내지 5 중량부 인 것이 가장 바람직하다. Here, the beverage composition of the present invention is characterized by mixing the plant extract, milk thistle extract, and calcium nano collagen peptide of the dermis, garlic root, goji berry and dandelion in a specific weight ratio, and specifically, the composition of the present invention is suitable for a hangover. It can be appropriately adjusted depending on the severity of symptoms, the degree of symptom progression, and the health of the liver, but the amount of the plant mixed extract is 70 to 90 parts by weight, specifically 70 to 80 parts by weight, relative to the total weight of the composition, and the milk thistle extract is 1 to 10 parts by weight, specifically 1 to 5 parts by weight, the calcium nano-collagen peptide is most preferably 0.3 to 10 parts by weight, specifically 0.3 to 5 parts by weight.
각 성분이 상기 범위 내로 포함되는 경우, 최적의 숙취 해소 및 간 기능 개선 효과를 얻을 수 있다. 상기 식물 혼합 추출물이 상기 범위보다 적게 포함되거나 상기 밀크씨슬 추출물이 상기 범위보다 적게 포함된 경우에는 알코올 분해 효과가 다소 떨어져 숙취 해소 효과나 간 기능 개선 효과가 미미할 수 있다. When each component is included within the above range, an optimal hangover relief and liver function improvement effect can be obtained. When the plant mixed extract is included in less than the above range or the milk thistle extract is included in less than the above range, the alcohol decomposition effect is somewhat lowered, so the effect of relieving a hangover or improving liver function may be insignificant.
한편, 본 발명의 음료 조성물은 울금 추출물, 과라나 추출물, 나린진 추출물 및 헤스페리딘 추출물로 이루어진 군에서 선택된 하나 이상을 더 포함할 수 있으며, 구체적으로는 울금 추출물, 과라나 추출물, 나린진 추출물 및 헤스페리딘 추출물을 더 포함할 수 있다. 보다 구체적으로 본 발명의 조성물 총 중량에 대비 울금 추출물은 0.01 내지 0.1 중량부, 과라나 추출물은 0.1 내지 0.5 중량부, 나린진 추출물은 0.01 내지 0.1 중량부 및 헤스페리딘 추출물은 0.1 내지 0.5 중량부를 포함하는 것을 특징으로 한다. On the other hand, the beverage composition of the present invention may further include one or more selected from the group consisting of turmeric extract, guarana extract, naringin extract and hesperidin extract, specifically, turmeric extract, guarana extract, naringin extract and hesperidin extract. can do. More specifically, the composition of the present invention contains 0.01 to 0.1 parts by weight of the turmeric extract, 0.1 to 0.5 parts by weight of the guarana extract, 0.01 to 0.1 parts by weight of the naringin extract, and 0.1 to 0.5 parts by weight of the hesperidin extract relative to the total weight of the composition of the present invention. do it with
울금(Curcuma longa)에는, 황색 색소 Curcumin을 비롯해서 Turmerone, zingiberene, 담즙 분비 작용이 있는 PTMC 등의 성분이 포함되어 있다. 울금은 숙취 해소, 간 해독 촉진, 이뇨, 항 출혈, 항균, 항궤양, 혈중콜레스테롤 억제 등의 효능이 있고, 간염, 특히 만성 C형 등에 대한 효능과 활성 산소의 제거, 항산화 효능이 있어 간 기능 개선에 도움이 된다. Turmeric (Curcuma longa) contains the yellow pigment Curcumin, as well as components such as Turmerone, zingiberene, and PTMC with bile secretion. Turmeric is effective in relieving hangover, promoting liver detoxification, diuresis, anti-bleeding, antibacterial, anti-ulcer, and blood cholesterol suppression. is helpful for
과라나(Guarana)는, 카페인 함유량이 높아 각성 효과가 뛰어나서 청량 음료, 에너지 음료, 숙취 해소 음료, 강장제 등의 원료로 사용된다. 과라나는 커피 콩보다 2배 많은 농도의 카페인을 함유하고 있기 때문에, 카페인을 함유하고 있는 다른 식물들과 마찬가지로, 과라나의 높은 카페인 농도는 방어적 독소 작용을 하여, 다른 병원균으로부터 과라나 열매나 씨앗을 보호하는 역할을 한다. Guarana is used as a raw material for soft drinks, energy drinks, hangover relieving drinks, and tonics because of its high caffeine content and excellent arousal effect. Because guarana contains twice as much caffeine as coffee beans, like other caffeinated plants, the high caffeine concentration in guarana acts as a protective toxin, protecting the guarana fruit or seed from other pathogens. plays a role
나린진(Naringin)과 헤스페리딘(Hesperidin)은, 플라보노이드 유도체로서, 정균 및 항균작용, 항산화 작용, 아스코르빈산 상승 작용, 항암 작용, 항위궤양(알콜로부터 보호) 작용을 통해 간 독성을 회복하여 중금속 해독 작용을 하며, 식품에 향미증진제로도 사용될 수 있다. Naringin and Hesperidin are flavonoid derivatives that restore liver toxicity through bacteriostatic and antibacterial action, antioxidant action, ascorbic acid synergism, anticancer action, and anti-ulcer (protection from alcohol) action, thereby detoxifying heavy metals. It can also be used as a flavor enhancer in food.
또한, 본 발명의 음료 조성물은 타우린, 히스티딘, 아르지닌, 라이신, 글라이신, 트레오닌, 글루타민, 메티오닌 및 아스파라긴으로 이루어진 군에서 선택된 하나 이상의 아미노산을 더 포함할 수 있으며, 구체적으로 타우린, 메티오닌 및 아스파라긴을 모두 포함하는 경우, 간의 피로 개선에 탁월한 효과가 있다. 타우린은 자양강장제 또는 피로회복제 등 드링크 제품의 주성분으로 주로 사용되며, 알코올성 간 질환 개선에 뛰어난 효과가 있고, 메티오닌은 간의 지방을 감소시키며 신장을 보호하며, 아스파라긴은 간에서 알코올을 분해하는 효소의 생성을 도와 숙취에 탁월한 효과가 있다. In addition, the beverage composition of the present invention may further include one or more amino acids selected from the group consisting of taurine, histidine, arginine, lysine, glycine, threonine, glutamine, methionine and asparagine, specifically taurine, methionine and asparagine all When included, it has an excellent effect on improving liver fatigue. Taurine is mainly used as a main ingredient in drink products such as nourishing tonics or fatigue recovery agents. It has an excellent effect on improving alcoholic liver disease. Methionine reduces fat in the liver and protects the kidneys. Asparagine produces enzymes that break down alcohol in the liver. It has an excellent effect on hangover.
또한, 본 발명의 음료 조성물은 덱스트로스, 수크로오스, 락토스, 수크랄로스, 벌꿀, 프락토 올리고당, 이노시톨, 솔비톨, 만니톨, 말티톨, 자일리톨, 시클로덱스트린 및 에리스리톨로 이루어진 군에서 선택된 하나 이상의 당 또는 당알코올을 더 포함할 수 있으며, 구체적으로는 벌꿀, 프락토 올리고당 및 이노시톨을 더 포함할 수 있다. In addition, the beverage composition of the present invention further contains one or more sugars or sugar alcohols selected from the group consisting of dextrose, sucrose, lactose, sucralose, honey, fructooligosaccharide, inositol, sorbitol, mannitol, maltitol, xylitol, cyclodextrin and erythritol. It may include, specifically, honey, fructooligosaccharide and may further include inositol.
본 발명에서 상기 벌꿀, 프락토 올리고당 및 이노시톨은 감미료로 사용될 수 있으며, 구토 및 피로감에 따른 혈액 내 포도당 부족 분을 보충해줄 수 있다. In the present invention, the honey, fructooligosaccharide and inositol can be used as a sweetener, and can compensate for the lack of glucose in the blood due to vomiting and fatigue.
또한, 본 발명의 음료 조성물은 구연산 칼슘 및 무수 구연산을 더 포함할 수 있다. 구연산 칼슘 및 무수 구연산은 식품의 칼슘 강화제 또는 완충액, 산도 조절제, 산미제, pH조절제, 산화방지제, 과일향 보조제, 보존성 상승제 또는 산미료와 같은 식품 첨가제로 주로 사용되며, 알코올 분해를 촉진해 숙취 해소 효과가 뛰어나고, 미네랄 공급으로 피로 회복에 도움이 된다. In addition, the beverage composition of the present invention may further include calcium citrate and anhydrous citric acid. Calcium citrate and anhydrous citric acid are mainly used as food additives such as calcium fortifiers or buffers, acidity regulators, acidulants, pH regulators, antioxidants, fruit flavor supplements, preservation enhancers, or acidulants in food. It is effective and helps in recovering from fatigue by supplying minerals.
또한, 본 발명의 음료 조성물은 비타민 B1(티아민), B2(리보플라빈), B3(니코틴아마이드) 및 B6(피리독신)으로 이루어진 군에서 선택된 하나 이상을 더 포함할 수 있다. In addition, the beverage composition of the present invention may further include at least one selected from the group consisting of vitamins B 1 (thiamine), B 2 (riboflavin), B 3 (nicotinamide) and B 6 (pyridoxine).
상기 비타민 B 복합체는 세포 대사에서 중요한 역할을 수행하는 수용성 비타민들이다. 구체적으로 면역 체계 및 신경계 기능을 강화시키며, 근육 건강을 유지시키며, 신진대사 작용을 촉진시키는 효과가 있어 알코올의 대사를 촉진시키고, 체 내의 수분 균형에 도움을 줄 수 있다. The vitamin B complex is water-soluble vitamins that play an important role in cellular metabolism. Specifically, it strengthens the immune system and nervous system functions, maintains muscle health, and has the effect of accelerating metabolism, thus promoting alcohol metabolism and helping to balance water in the body.
상기 본 발명의 음료 조성물은 상기 유효 성분 외에 다른 유효 성분 및/또는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 음료의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.The beverage composition of the present invention may include other active ingredients and/or food supplementary additives in addition to the active ingredients, and may further include suitable carriers, excipients and diluents commonly used in the manufacture of beverages. have.
즉, 영양제, 비타민, 전해질, 풍미제, 착색제, 중진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 감미제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 추가로 함유할 수 있다. 상기 성분들은 독립적으로 또는 조합하여 추가될 수 있다.That is, nutrients, vitamins, electrolytes, flavoring agents, colorants, thickeners, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, sweeteners, preservatives, glycerin, alcohol, carbonated beverages It may further contain a carbonation agent, etc. used for The above components may be added independently or in combination.
또한, 본 발명은 상기 음료용 조성물을 포함하는 숙취 해소 및 간 기능 개선용 음료를 제공한다. In addition, the present invention provides a beverage for relieving hangover and improving liver function, comprising the composition for beverage.
본 발명의 음료 조성물은 음료 전체의 부피 25 ml 를 기준으로 1 g 내지 15 g, 구체적으로는 1 g 내지 10 g의 비율로 포함될 수 있고 나머지는 정제수를 포함할 수 있다. 권장 섭취량은 최대 1일 1~2회, 1회당 1포일 수 있다.The beverage composition of the present invention may be included in a ratio of 1 g to 15 g, specifically 1 g to 10 g, based on 25 ml of the total volume of the beverage, and the remainder may include purified water. The recommended intake can be up to 1 to 2 times a day, 1 package per time.
섭취방법으로는 음료 조성물을 액상의 음료로 제조하여 섭취하거나 저농도로 희석시켜 물 대신 음용할 수 있다.As an intake method, the beverage composition may be prepared as a liquid beverage and consumed or diluted to a low concentration and consumed instead of water.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다. Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention. However, the present invention may be embodied in several different forms and is not limited to the embodiments described herein.
제조예 1Preparation Example 1
하기 표 1 조성의 식물 혼합물을 제조하여 식물 혼합 추출물을 제조하였다. 구체적으로, 각 원료는 경동시장(서울, 제기동)에서 각각 구입하여 추출 원료로 사용하였다. 상기 각각의 추출 원료에 정제수를 넣고, 약 100 ℃ 약 12시간 이상 추출 후 여과하여 액상의 식물 혼합 추출물을 수득하였으며, 추출 수율은 약 75%이다. A plant mixture of the composition of Table 1 was prepared to prepare a plant mixture extract. Specifically, each raw material was purchased from Gyeongdong Market (Seoul, Jegi-dong) and used as an extraction raw material. Purified water was added to each of the extraction raw materials, and after extraction at about 100° C. for about 12 hours or more, filtration was performed to obtain a liquid plant mixed extract, and the extraction yield was about 75%.
제조예 2Preparation 2
생선 껍질과 해파리의 해양성 콜라겐을 정제수로 세척하여 불순물을 제거하고 원료 1 kg에 대하여 정제수 4 리터를 넣고 쵸파로 50 ㎛로 분쇄 하였다.Fish skin and marine collagen of jellyfish were washed with purified water to remove impurities, and 4 liters of purified water was added to 1 kg of raw material and crushed to 50 μm with a chopper.
이후 오존을 통과시켜 탈취 처리한 원료를 구연산 0.5 % 용액에 넣고 펩신의 단백질분해효소 0.5 w%를 첨가하여 55 ℃로 24 시간 동안 가수분해시켜 분자량 300 Da 내지 400 Da, 사이즈 1 nm 내지 5 nm의 콜라겐 펩타이드를 얻었다. After that, the raw material deodorized by passing ozone is put into a 0.5% solution of citric acid, and 0.5 w% of pepsin protease is added and hydrolyzed at 55° C. for 24 hours to obtain a molecular weight of 300 Da to 400 Da, size 1 nm to 5 nm Collagen peptides were obtained.
칼슘 나노 콜라겐 펩타이드의 제조를 위하여, 콜라겐 펩타이드 100 중량 대비 탄산칼슘을 이용하여 칼슘 함량이 1 내지 20 중량부가 되도록 첨가하고, 55 ℃에서 효소 가수분해하면서 킬레이트화 반응을 시켰으며, 이후 분무 건조기를 이용하여 건조시켜 칼슘 나노 콜라겐 펩타이드의 킬레이트 복합체 분말을 제조하였다.For the preparation of calcium nano-collagen peptide, calcium carbonate was added so that the calcium content was 1 to 20 parts by weight relative to 100 weight of the collagen peptide, followed by enzymatic hydrolysis at 55 ° C., followed by chelation reaction, and then using a spray dryer and dried to prepare a chelate complex powder of calcium nano-collagen peptide.
실시예 1Example 1
제조예 1의 식물 혼합 추출물 및 제조예 2의 칼슘 나노 콜라겐 펩타이드에 추가 원료를 배합하여 하기 표 2 조성의 숙취 해소 및 간 기능 개선용 음료 조성물을 제조하였다. Additional raw materials were mixed with the plant mixed extract of Preparation Example 1 and the calcium nano-collagen peptide of Preparation Example 2 to prepare a beverage composition for relieving hangover and improving liver function of the composition in Table 2 below.
비교예 1Comparative Example 1
상기 실시예 1에서 식물 혼합 추출물을 혼합하지 않은 것을 제외하고는 실시예 1과 동일하게 음료 조성물을 제조하였다.A beverage composition was prepared in the same manner as in Example 1, except that the plant mixed extract was not mixed in Example 1.
비교예 2Comparative Example 2
상기 실시예 1에서 밀크씨슬 추출물을 혼합하지 않은 것을 제외하고는 실시예 1과 동일하게 음료 조성물을 제조하였다. A beverage composition was prepared in the same manner as in Example 1, except that the milk thistle extract was not mixed in Example 1.
비교예 3Comparative Example 3
상기 실시예 1에서 칼슘 나노 콜라겐 펩타이드를 혼합하지 않은 것을 제외하고는 실시예 1과 동일하게 음료 조성물을 제조하였다. A beverage composition was prepared in the same manner as in Example 1, except that the calcium nano-collagen peptide was not mixed in Example 1.
비교예 4Comparative Example 4
상기 실시예 1에서 식물 혼합 추출물 및 밀크씨슬 추출물을 조성물 총 중량 대비 60 중량부 및 1.0 중량부로 혼합한 것을 제외하고는 실시예 1과 동일하게 음료 조성물을 제조하였다.A beverage composition was prepared in the same manner as in Example 1, except that in Example 1, 60 parts by weight and 1.0 parts by weight of the plant mixed extract and milk thistle extract were mixed with respect to the total weight of the composition.
실험예 1: 숙취 해소 및 간 기능 개선 동물 실험 Experimental Example 1: Hangover Relief and Liver Function Improvement Animal Experiment
1-1. 동물 실험의 준비1-1. Preparation of animal experiments
6주령의 ICR(Institute of Cancer Research) 마우스 수컷 18마리를 7일 동안, 온도 22±3 ℃, 상대습도 50±20%, 조도 150-300 Lux 조건의 실험실에 적응시킨 후 7주령이 되었을 때 시험에 사용하였다. 적응기간 동안, 음용수로는 R/O system을 이용한 역삼투압 초순수를, 사료로는 방사선 멸균 사료(Purina)를 자유섭취시켰으며, 시험 개시 시 시험동물들 간의 체중 편차 범위가 평균 ± 20 % 이내가 되도록 하였다. 상기 시험동물들은 투여 당일 무작위법으로 각 군의 평균 체중이 가능한 한 균등하게 배분되도록 대조군(식염수), 실시예 1 및 비교예 1 내지 4의 6개의 그룹을 군당 3마리로 구성하였다. 시험 중 개체 식별을 위해서는 미부 표시법을 사용하였다.18 6-week-old ICR (Institute of Cancer Research) mice were acclimatized to a laboratory under the conditions of 22±3 ℃ temperature, 50±20% relative humidity, and 150-300 Lux illumination for 7 days, and then tested when they reached 7 weeks of age. was used for During the adaptation period, reverse osmosis ultrapure water using R/O system was used as drinking water, and radiation sterilized feed (Purina) was freely consumed as feed. made to be The test animals consisted of 3 animals per group of 6 groups of the control group (saline), Examples 1 and 4, so that the average body weight of each group was distributed as evenly as possible by a randomized method on the day of administration. The tail marking method was used for individual identification during the test.
1-2. 통계처리 및 분석1-2. Statistical processing and analysis
체중 및 혈청 분석(에탄올, 아세트알데하이드, CYP2E1) 결과의 통계적 유의성은 대조값으로부터의 변동을 스튜던트 t-검정(student's t-test)에 의해 분석하였으며, p 값이 0.05 미만인 경우 통계적으로 유의한 것으로 판정하였다. 구체적으로, p 값이 0.05 미만인 경우 *, 0.01 미만인 경우 †로 표시하여 유의성의 차이를 판단하였다.The statistical significance of the results of body weight and serum analysis (ethanol, acetaldehyde, CYP2E1) was analyzed by student's t-test for variation from the control value, and was determined to be statistically significant when the p value was less than 0.05. did. Specifically, a difference in significance was determined by indicating * when the p value was less than 0.05 and † when the p value was less than 0.01.
1-3. 숙취 개선 효과 확인 1-3. Check hangover improvement effect
에탄올(씨그마알드리치코리아)을 정제수 (Distilled water)에 희석하여 60% 에탄올 용액을 조제하였다. 투여 직전 조제되어 안정성, 순도 등 별도의 분석을 실시하지 않았다.Ethanol (Sigma-Aldrich Korea) was diluted in distilled water to prepare a 60% ethanol solution. It was prepared just before administration, so no separate analysis was performed on stability and purity.
식이에 의한 알코올 흡수 및 분해의 차이를 제거하기 위해 시험물질 투여 18시간 전부터 금식시켰다. 각 그룹 당 3마리의 마우스를 사용하였다. In order to eliminate the difference in alcohol absorption and degradation by diet, they were fasted 18 hours before test substance administration. Three mice were used in each group.
구체적으로, 실험동물 그룹 별로 식염수, 실시예 1 및 비교예 1 내지 4의 음료 조성물을 에탄올 섭취 30분 전에 경구투여하였다. 그 다음 60% 에탄올 200 μl를 경구투여 하였다. 에탄올 섭취 2시간 후에 마취제 (zoletil, Rumpun) 의 5:1 혼합물을 1/7로 희석하여 6 mg/kg B.W.으로 복강주사 함)를 사용하여 마취 한 후, 개복하여 심장 채혈을 실시하였다. 전혈을 원심분리시켜(4℃, 10,000 rpm, 15분) 혈청을 분리하고, -80℃ 에 보관한 후 사용하였다. 혈중 아세트알데하이드는 분리된 혈청을 사용하여 ELISA kit (Acetaldehyde kit, Roche, 스위스)로 측정하였다. 혈중 에탄올은 분리된 혈청을 사용하여 ELISA kit (Ethanol kit, Roche, 스위스)로 측정하였고, CYP2E1도 분리된 혈청을 이용해 ELISA kit(Mouse Cytochrome p450 2E1 (CYP2E1) ELISA kit, 중국)로 측정하였다.Specifically, saline, the beverage compositions of Examples 1 and Comparative Examples 1 to 4 for each experimental animal group were orally administered 30 minutes before ingestion of ethanol. Then, 200 μl of 60% ethanol was orally administered. After 2 hours of ingestion of ethanol, a 5:1 mixture of anesthetics (zoletil, Rumpun) was diluted 1/7 and intraperitoneally injected at 6 mg/kg B.W. Whole blood was centrifuged (4°C, 10,000 rpm, 15 minutes) to separate serum, and stored at -80°C before use. Blood acetaldehyde was measured with an ELISA kit (Acetaldehyde kit, Roche, Switzerland) using the isolated serum. Blood ethanol was measured with an ELISA kit (Ethanol kit, Roche, Switzerland) using the isolated serum, and CYP2E1 was also measured using the isolated serum with an ELISA kit (Mouse Cytochrome p450 2E1 (CYP2E1) ELISA kit, China).
1-4. 혈장 내 에탄올 농도의 비교1-4. Comparison of Ethanol Concentrations in Plasma
각 그룹별 혈장 내 에탄올 농도의 측정 결과는 하기 표 3과 같다. The measurement results of plasma ethanol concentrations for each group are shown in Table 3 below.
상기 표 3에서 보는 바와 같이, 본 발명의 숙취 해소 및 간 기능 개선용 음료 조성물을 투여한 실시예 1 그룹은 가장 유의미하게 낮아진 에탄올 농도를 보였다. 그리고, 본 발명의 음료 조성물의 혼합비와 상이한 비교예 4는 실시예 1보다는 에탄올 분해 효과가 덜한 것을 확인할 수 있었다. As shown in Table 3, the Example 1 group administered with the beverage composition for relieving hangover and improving liver function of the present invention showed the most significantly lowered ethanol concentration. And, Comparative Example 4 different from the mixing ratio of the beverage composition of the present invention was confirmed to have less ethanol decomposition effect than Example 1.
한편, 일부 성분이 포함되지 않은 비교예 1 내지 3은 실시예 1 및 실시예 4 보다 혈액 내 에탄올 농도가 높은 것으로 보아, 에탄올 분해 효과가 확연히 떨어진다는 것을 알 수 있었다. On the other hand, Comparative Examples 1 to 3, in which some components were not included, showed that the concentration of ethanol in the blood was higher than that of Examples 1 and 4, indicating that the ethanol decomposition effect was significantly lowered.
1-5. 혈장 내 CYP2E1 농도의 비교1-5. Comparison of CYP2E1 Concentrations in Plasma
각 그룹별 혈장 내 CYP2E1 농도의 측정 결과는 하기 표 4와 같다. The measurement results of CYP2E1 concentrations in plasma for each group are shown in Table 4 below.
상기 표 4에서 보는 바와 같이, 본 발명의 숙취 해소 및 간 기능 개선용 음료 조성물을 투여한 실시예 1 그룹에서 CYP2E1 농도가 다른 그룹들에 비해 유의미하게 낮은 농도를 보이는 것을 확인할 수 있었다. 그리고 비교예 4 그룹은 비교예 1 내지 3 보다는 낮지만 실시예 1보다는 높은 농도를 보이는 것을 확인할 수 있었다. 일부 성분이 포함되지 않은 비교예 1 내지 3은 실시예 1 및 실시예 4 보다 혈장 내 CYP2E1 농도가 높은 것을 확인할 수 있었다. As shown in Table 4, it was confirmed that the CYP2E1 concentration in the Example 1 group administered with the beverage composition for relieving a hangover and improving liver function of the present invention was significantly lower than that of other groups. And it was confirmed that the group of Comparative Example 4 showed a concentration lower than that of Comparative Examples 1 to 3 but higher than that of Example 1. Comparative Examples 1 to 3 in which some components were not included were confirmed to have higher plasma CYP2E1 concentrations than Examples 1 and 4.
따라서, 본 발명의 음료 조성물은 알코올성 간 손상의 유발과 관련이 있는 CYP2E1 발현을 저해하는 것을 알 수 있었다. Therefore, it was found that the beverage composition of the present invention inhibits CYP2E1 expression, which is related to the induction of alcoholic liver damage.
실험예 2: 인간 대상 간이 임상실험Experimental Example 2: Human Subject Simplified Clinical Trial
2-1. 호흡기 에탄올 농도 측정 2-1. Determination of Respiratory Ethanol Concentration
20세부터 50세 이하의 남자 각각 6명에게 에탄올 농도 17도 시판소주(참이슬) 6ml/kg/bw를 5분 내에 섭취하도록 하고, 대조군(식염수), 실시예 1 및 비교예 1 내지 4 각각의 300mg/kg을 에탄올 섭취 전/후 30분에 2회 복용시키고, 음주측정기(Breathlizer, (주)센텍코리아, AL9000)로 에탄올 섭취 후 1, 2, 3시간에 알코올 농도를 측정하여, 그 결과를 표 5에 나타내었다.Six males aged 20 to 50 years old were each ingested 6ml/kg/bw of commercially available soju (Chamisul) with an ethanol concentration of 17 degrees within 5 minutes, and each of the control group (saline), Examples 1 and Comparative Examples 1 to 4 300mg/kg was taken twice 30 minutes before/after ethanol intake, and the alcohol concentration was measured 1, 2, and 3 hours after ingestion of ethanol with a breathalyzer (Breathlizer, Sentech Korea, AL9000), and the result was measured Table 5 shows.
상기 표 5에서 보는 바와 같이, 본 발명의 숙취 해소 및 간 기능 개선용 음료 조성물을 투여한 실시예 1 그룹에서 호흡기 알코올 농도가 다른 그룹에 비해 현저히 낮은 것을 확인할 수 있었다. 이를 통해 본 발명의 음료 조성물은 숙취 해소 능력이 뛰어나 호흡기 알코올 농도를 탁월하게 감소시키는 효과가 있음을 알 수 있었다. As shown in Table 5, it was confirmed that the respiratory alcohol concentration in Example 1 group administered with the beverage composition for relieving hangover and improving liver function of the present invention was significantly lower than that of other groups. Through this, it was found that the beverage composition of the present invention has excellent hangover relieving ability and has the effect of excellently reducing the respiratory alcohol concentration.
2-2. 숙취 해소 효과 관능 평가2-2. Sensory evaluation of hangover relief effect
본 발명의 조성물이 실제 음주 다음날 숙취를 해소하는지 확인하기 위해, 음주 후 본 발명의 조성물을 복용하게 하였다.In order to confirm whether the composition of the present invention actually relieves a hangover the day after drinking, the composition of the present invention was taken after drinking.
각 그룹당 건강한 20세 이상의 성인 남녀 10명을 대상으로 실험하였고, 실험을 위해 실험 대상자들을 대상으로 동량의 식사와 함께 300㎖의 소주를 60분에 걸쳐 마시도록 하였고, 음주 직후, 대조군(식염수), 실시예 1 및 비교예 1 내지 4의 조성물을 각각 4g씩 섭취하게 하였다. 이들 그룹이 다음 날 아침에 확인한 숙취 제거 효과, 소화 효과, 두통 정도에 대한 항목을, '효과 없음'을 1로 하고 '효과가 가장 높음' 을 5로 하여, 5단계(1~5)의 범위 내로 작성하여, 하기 표 6에 나타내었다.For each group, 10 healthy adult men and women over 20 years of age were tested. For the experiment, the subjects were instructed to drink 300 ml of soju over 60 minutes with the same amount of meal, immediately after drinking, as a control group (saline), Each of the compositions of Example 1 and Comparative Examples 1 to 4 was ingested by 4 g. The items for the hangover removal effect, digestive effect, and headache degree confirmed by these groups the next morning, 'No effect' as 1, and 'Highest effect' as 5, the range of 5 steps (1 to 5) was written and shown in Table 6 below.
상기 표 6에서 보는 바와 같이, 본 발명의 음료 조성물을 복용한 경우가 가장 높은 숙취 해소 효과가 있음을 확인할 수 있었다.As shown in Table 6, it was confirmed that the beverage composition of the present invention had the highest hangover relieving effect.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The above description of the present invention is for illustration, and those of ordinary skill in the art to which the present invention pertains can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive.
Claims (4)
상기 식물 혼합 추출물은 70 내지 90 중량부이고,
상기 밀크씨슬 추출물은 1 내지 10 중량부이며,
상기 칼슘-킬레이트 나노 콜라겐 펩타이드는 0.3 내지 5 중량부이고,
상기 울금 추출물은 0.01 내지 0.1 중량부이고,
상기 과라나 추출물은 0.1 내지 0.5 중량부이고,
상기 나린진 추출물은 0.01 내지 0.1 중량부이고,
상기 헤스페리딘 추출물은 0.1 내지 0.5 중량부인 것을 특징으로 하는 숙취 해소 및 간 기능 개선용 음료 조성물.
Including plant blend extracts of dermis, garlic root, goji berry and dandelion, milk thistle extract, calcium-chelate nano collagen peptide, turmeric extract, guarana extract, naringin extract and hesperidin extract, compared to the total weight of the composition
The plant mixed extract is 70 to 90 parts by weight,
The milk thistle extract is 1 to 10 parts by weight,
The calcium-chelate nano collagen peptide is 0.3 to 5 parts by weight,
The turmeric extract is 0.01 to 0.1 parts by weight,
The guarana extract is 0.1 to 0.5 parts by weight,
The naringin extract is 0.01 to 0.1 parts by weight,
The hesperidin extract is a beverage composition for relieving a hangover and improving liver function, characterized in that 0.1 to 0.5 parts by weight.
상기 조성물은 타우린, 히스티딘, 아르지닌, 라이신, 글라이신, 트레오닌, 글루타민, 메티오닌 및 아스파라긴으로 이루어진 군에서 선택된 하나 이상의 아미노산을 더 포함하는 것인 숙취 해소 및 간 기능 개선용 음료 조성물.
According to claim 1,
The composition further comprises one or more amino acids selected from the group consisting of taurine, histidine, arginine, lysine, glycine, threonine, glutamine, methionine and asparagine.
상기 조성물은 구연산 칼슘 및 무수 구연산을 더 포함하는 것인 숙취 해소 및 간 기능 개선용 음료 조성물.According to claim 1,
The composition is a beverage composition for relieving a hangover and improving liver function that further comprises calcium citrate and anhydrous citric acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200076182A KR102433586B1 (en) | 2020-06-23 | 2020-06-23 | Food composition for relieving hangover and improving hepatic function |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200076182A KR102433586B1 (en) | 2020-06-23 | 2020-06-23 | Food composition for relieving hangover and improving hepatic function |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210157987A KR20210157987A (en) | 2021-12-30 |
KR102433586B1 true KR102433586B1 (en) | 2022-08-18 |
Family
ID=79178897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200076182A KR102433586B1 (en) | 2020-06-23 | 2020-06-23 | Food composition for relieving hangover and improving hepatic function |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102433586B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102642547B1 (en) * | 2022-11-11 | 2024-03-05 | 한국식품연구원 | Composition for improving relieving hangover and liver function comprising the Levilactobacillus brevis WiKim0168 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009511066A (en) * | 2005-10-13 | 2009-03-19 | グ、ジェニファー、エル. | Minerals, collagens and chelates and their production and use |
KR102056108B1 (en) * | 2019-06-12 | 2019-12-16 | 농업회사법인제주황금꽃벵이주식회사 | Composition for removing hangover and improving liver function |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100403721B1 (en) | 2001-01-31 | 2003-11-05 | (주)생명의나무 | Lower alcohol insoluble extract and a polysaccharide therein isolated from hovenia dulcis var. koreana nakai having antihepatotoxic and anti-hangover activity and composition containing same |
KR20020081995A (en) | 2001-04-23 | 2002-10-30 | (주)드리고 | Compound foods curing Hepato-toxicity and hangover, their formulations, and manufacturing methods |
KR20020092562A (en) * | 2001-06-04 | 2002-12-12 | 정풍한방제약주식회사 | Functional beverage, tea composition and a preparation process thereof |
-
2020
- 2020-06-23 KR KR1020200076182A patent/KR102433586B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009511066A (en) * | 2005-10-13 | 2009-03-19 | グ、ジェニファー、エル. | Minerals, collagens and chelates and their production and use |
KR102056108B1 (en) * | 2019-06-12 | 2019-12-16 | 농업회사법인제주황금꽃벵이주식회사 | Composition for removing hangover and improving liver function |
Also Published As
Publication number | Publication date |
---|---|
KR20210157987A (en) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101301094B1 (en) | Composition for relieving hangover or improving liver function | |
KR101433188B1 (en) | Composition For Relieving Alcohol-induced Hangover Comprising Starch, Amino Acids, Active Complex Vitamin And Oriental Herb Medicine materials AND, The Manufacturing Method Thereof | |
KR101593618B1 (en) | Composition for improving bioavailability of saponin | |
KR100510239B1 (en) | Method for preparing a composition containing corn silk and dietary fibre | |
KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
KR20180091311A (en) | Composition for Respiratory Symptoms Containing Red Ginseng Extract | |
KR100976241B1 (en) | Extract of sedum sarmentosum for alcohol oxidation and relieves hangover | |
KR102457306B1 (en) | Health function food composition comprising lactobacillus for improving skin and vowel function and method of preparing the same | |
KR102433586B1 (en) | Food composition for relieving hangover and improving hepatic function | |
KR102322276B1 (en) | Beverage composition for preventing obesity and relieving edema | |
KR20140046233A (en) | A composition and functional food comprising an extracts of rosa rugosa preventing or treating a physical stress-involved disease | |
KR100768830B1 (en) | Extract of echinosophora koreensis removing hangover and having anti-oxidant activity | |
KR20160096294A (en) | Crickets for improved liver function, liver cancer, hangover solutions, fatigue recovery and food compositions comprising the same | |
KR102127411B1 (en) | Composition comprising natural complex extract for protecting liver and relieving hangover | |
KR102235563B1 (en) | Composition for fatigue recovery and sexual function improvement containing high content of arginine | |
KR101626642B1 (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
KR100549089B1 (en) | A Health Care Composition for treating or preventing intestinal disease and constipation | |
KR20140036966A (en) | Composition for improving exercise capacity or a composition for reducing fatigue using leaves of sasa quelpaertensis | |
KR101350222B1 (en) | An alcohol detoxification composition comprising fruit extract of Camellia japonica | |
KR20180006612A (en) | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof | |
KR101594349B1 (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising processed Panax species plant leaf extract | |
KR102577328B1 (en) | Composition for enhancing immunity comprising at least two herbal extracts as an active ingredient | |
KR100684436B1 (en) | Composition comprising the extract of dioscorea quinqueloba and acanthopanax senticosus showing anti-oxidative, anti-aging by anti-lipidperoxidative, anti-inflammatory and discharge of phlegm activity | |
KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |